Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.200
-0.030 (-2.44%)
At close: Dec 5, 2025, 4:00 PM EST
1.210
+0.010 (0.83%)
After-hours: Dec 5, 2025, 5:01 PM EST
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus Oncology stock have an average target of 4.51, with a low estimate of 1.05 and a high estimate of 7.00. The average target predicts an increase of 275.83% from the current stock price of 1.20.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 4, 2025.
Analyst Ratings
The average analyst rating for Coherus Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +233.33% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +483.33% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | -12.50% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +483.33% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +483.33% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
44.64M
from 266.96M
Decreased by -83.28%
Revenue Next Year
74.67M
from 44.64M
Increased by 67.29%
EPS This Year
-1.49
from 0.25
EPS Next Year
-0.95
from -1.49
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.3M | 94.1M | ||||
| Avg | 44.6M | 74.7M | ||||
| Low | 41.2M | 60.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -81.5% | 110.8% | ||||
| Avg | -83.3% | 67.3% | ||||
| Low | -84.6% | 36.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.40 | -0.53 | ||||
| Avg | -1.49 | -0.95 | ||||
| Low | -1.50 | -1.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.